Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

ESMO 2026: Belantamab Mafodotin–Based Quadruplet Shows High Response Rates in Newly Diagnosed Multiple Myeloma

By: Wendy LaGrego
Posted: Monday, November 9, 2026

The combination of belantamab mafodotin (belamaf), daratumumab, lenalidomide, and dexamethasone (Bela-DRd) demonstrated high response rates and measurable residual disease (MRD) negativity in transplant-ineligible patients with newly diagnosed multiple myeloma, according to findings from the phase I/II Bela-DRd study presented at the 2026 European Society for Medical Oncology (ESMO) Congress (Abstract 1454O). Meletios A. Dimopoulos, MD, and colleagues evaluated the efficacy and safety of the four-drug regimen, with particular attention given to ocular adverse events.

Study Details

The open-label Bela-DRd study enrolled patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplantation. The first part of the study established the belamaf dosage at 1.9 mg/kg every 8 weeks, with the dosing interval subsequently extended to every 12 weeks, as the recommended phase II regimen.

The second part, a dose-expansion phase, evaluated the safety and efficacy of the recommended regimen in two cohorts (groups A and B). Ocular toxicity was monitored and managed by an ophthalmologist in group A and by a hematologist using the Vision-Related Anamnestic tool in group B.

Part 1 included 24 patients with a median age of 73 years; 54.2% were male. Part 2 enrolled 12 patients with a median age of 74 years. Median follow-up was 34.3 months in part 1 and 17.9 months in part 2.

Clinical Efficacy

In part 1, the overall response rate was 91.7%, with 70% of patients achieving a complete response or better. MRD negativity was documented in 13 of 16 evaluable patients (81.3%).

In part 2, the overall response rate was also 91.7% (11 of 12 patients), and 5 of 7 evaluable patients (71.4%) achieved MRD negativity. The median time to a partial response or better was 1.1 months.

At 18 months, progression-free survival was 91.7% (95% confidence interval [CI] = 76.4%–97.2%) in the overall study population and 87.5% (95% CI = 66.1%–95.8%) in the population receiving the recommended phase II regimen.

Safety and Ocular Toxicity

Ocular adverse events led to the omission of 105 of 380 planned belamaf doses (27.6%) in part 1, compared with 13 of 113 planned doses (11.5%) in part 2.

Grade 3 or higher declines in best-corrected visual acuity occurred in 10.4% of ocular assessments in part 1, compared with 3.9% and 5.3% of assessments in part 2 groups A and B, respectively. Grade 2 or higher keratopathy occurred in 20.2% of assessments in part 1 and 6.7% and 10.6% in part 2 groups A and B, respectively. Grade 3 or higher keratopathy was reported in 0.6% of assessments in part 1 and none in part 2.

Median resolution times for grade 2 or higher visual acuity–related ocular adverse events and keratopathy were 1.1 and 1.0 months, respectively, in part 1, and 1.9 and 1.0 months in part 2.

Fatigue was the most common grade 3 or higher nonocular adverse event, affecting 13 patients (54.2%) in part 1 and 6 patients (50.0%) in part 2; investigators attributed most cases to lenalidomide. Three fatal treatment-emergent adverse events occurred in part 1, whereas none were reported in part 2.

“BelaDRd, with belamaf administered every 2 to 3 months, demonstrated robust clinical activity, with rapid and deep responses and high MRD negativity rates with manageable toxicity,” the investigators concluded.

DISCLOSURE: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.